Patents by Inventor Hongxiang Hu

Hongxiang Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240139336
    Abstract: The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.
    Type: Application
    Filed: April 6, 2023
    Publication date: May 2, 2024
    Inventors: Yu Lei, Yee Sun Tan, Kanokwan Sansanaphongpricha, Duxin Sun, Hongwei Chen, Hongxiang Hu
  • Publication number: 20240059624
    Abstract: The present disclosure provides a Cellulosimicrobium cellulans strain and use thereof in straw field composting, belonging to the technical field of microorganisms. In the present disclosure, the Cellulosimicrobium cellulans strain is named Cellulosimicrobium cellulans MC29-GFP, and is deposited in the China General Microbiological Culture Collection Center (CGMCC), with a deposit number of CGMCC No. 25013. The Cellulosimicrobium cellulans MC29-GFP can promote the compost decomposition of straw in field. The experimental results show that the Cellulosimicrobium cellulans MC29-GFP significantly increases activities of cellulase and peroxidase in the straw during the decomposition compared with Bacillus amyloliquefaciens SQR9, thereby achieving rapid decomposition.
    Type: Application
    Filed: July 11, 2023
    Publication date: February 22, 2024
    Inventors: Zhengyu WEI, Chao MA, Zhong YIN, Ziyun ZHANG, Zhanqin HU, Xin WANG, Shengli SONG, Lanshan JIANG, Hongxiang HU, Zhen ZHANG, Xinxin YE
  • Patent number: 11701433
    Abstract: The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) an type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: July 18, 2023
    Assignee: The Regents of the University of Michigan
    Inventors: Yu Lei, Yee Sun Tan, Kanokwan Sansanaphongpricha, Duxin Sun, Hongwei Chen, Hongxiang Hu
  • Publication number: 20230183282
    Abstract: The present invention relates to methods, compounds, and compositions for treating viral infections, including COVID-19 viral infections. In certain embodiments, the compositions comprise: i) a remdesivir analog, ii) remdesivir or a remdesivir analog, and a surfactant, a cyclodextrin, or a combination thereof, iii) nanoparticles comprising albumin and remdesivir or remdesivir analog, iv) liposomes comprising lipids and remdesivir or remdesivir analog; and/or v) microparticles comprising PLA and/or PLGA, and remdesivir or remdesivir analog. In certain embodiments, the compositions are aqueous (e.g., for intravenous administration). In other embodiments, the compositions are nebulized or in the form of a dry powder (e.g., for inhalation by an infected subject).
    Type: Application
    Filed: April 1, 2021
    Publication date: June 15, 2023
    Inventors: Duxin Sun, Wei Gao, Hongxiang Hu, Mohamed Dit Mady Traore, Yudong Song, Bo Wen, Miao He, Hebao Yuan, Ruiting Li
  • Publication number: 20230025865
    Abstract: This disclosure provides compositions and methods for albumin nanoformulation of Bcl-2 and Bcl-xL inhibitor APG-1252 to suppress and/or inhibit growth of cancer cells (e.g., tumor cells). In particular, the present invention is directed to compositions comprising nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) APG-1252, methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings). Such nanoparticle formulations of APG-1252 are capable of increasing solubility, protecting against its degradation, reducing platelet toxicity, and expanding (improving) different indications to improve anticancer efficacy in various cancers and cancer metastasis in lymph nodes.
    Type: Application
    Filed: December 11, 2020
    Publication date: January 26, 2023
    Inventors: Duxin Sun, Wei Gao, Hongxiang Hu
  • Publication number: 20200129640
    Abstract: The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) an type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.
    Type: Application
    Filed: June 1, 2018
    Publication date: April 30, 2020
    Inventors: Yu Lei, Yee Sun Tan, Kanokwan Sansanaphongpricha, Duxin Sun, Hongwei Chen, Hongxiang Hu